The clones used for making the fragments were ordered (Table 5S ). The sequences of the fragments were introduced into the pET160-DEST vector (Invitrogen) using the 'Gateway®Technology with Clonase TM
2+
-Sepharose (Beullens et al., 2000) . His-eIF2β-(1-144), and His-Inhibitor 3 were produced as described previously (Wakula et al., 2006; Beullens et al., 1999; Lesage et al. 2007 ). The sequence of the fragments of AATK (corresponding to aminoacids 1130-1434, NP_001073864, clone ID: IRAKp961G2491Q2 from RZPD) and ANKDR28 (corresponding to aminoacids 908-1053, NP_056014, Clone ID: IRAKp961G23105Q2 from RZPD) were introduced into the pET160-DEST, as described for the fragments used in the screening. The sequences of the full length proteins are introduced into the pdEGFP-C using the 'Gateway®Technology (Invitrogen), made by classical subcloning or were received from other groups.
Gateway System
The following clones were obtained by the use of the described Gateway system: EGFPC11orf66, EGFP-C1orf71, EGFP-CHCHD3, EGFP-DLG3, EGFP-DYSFIP1, EGFP-FAM130A1, EGFP-SH2D4A, EGFP-SH3RF2. The sequences were introduced into the pdEGFP-C (n°2296) vector (Invitrogen) using the 'Gateway®Technology with Clonase TM ‫'װ‬ system (Invitrogen), yielding mammalian expression vectors for EGFP-tagged proteins. Classical cloning -EGFP-MPHOSPH10 was first introduced in pET160/GW/D-TOPO via Champion TM pET Directional TOPO ® Expression Kits with Lumio TM Techonology (Invitrogen) and flanked by restriction sites for the enzymes BglII and Kpn1. The flanked MPHOSPH10 was cutted with BglII and Kpn1 and ligated in pEGFP-C1.
